Caspofungin vs placebo for yeast infection in the belly (ICU)
Part of Infections clinical trials.
This Phase 3 trial studies whether caspofungin (an antifungal medicine) helps treat suspected or confirmed yeast (candidiasis) infections inside the abdomen in ICU patients after surgery. You would either receive caspofungin or a placebo, and the goal is to see which option works better and is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have national health insurance
- You are in the ICU after abdominal surgery for an intra-abdominal infection where yeast is suspected (peritonitis score 3 or higher) or proven by lab tests from fluid taken during surgery
- You (or your legal representative) can sign informed consent
- You are able to stay on the study treatment for the planned time
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how two antifungal medicines (anidulafungin and caspofungin) behave in the blood of critically ill ICU patients. It may help doctors better understand which dosing works best when patients have low blood protein levels or fluid leakage.
This trial tests how well rezafungin, an antifungal medicine, spreads in belly fluid when given during surgery for a suspected fungal infection in the abdomen. It aims to see if it's a good treatment option for patients needing abdominal surgery.
This trial tests whether a shorter course of the antifungal caspofungin (7 days total) is as effective as the usual longer treatment for people with uncomplicated candidemia, a yeast infection in the blood. Participating patients must already be on caspofungin and have shown clear blood cultures for 7 days.
This trial is testing how the body processes the antifungal drug rezafungin in people who may have a fungal infection in their abdomen (peritonitis or intra-abdominal candidiasis). It aims to understand how the drug works and if it can help when other antibiotics haven't worked.
This study looks at patients in the intensive care unit who have a new infection with Candida (a type of fungus) despite taking strong antibiotics. It aims to better understand and diagnose these serious infections.
This study tests how well and how safely the antifungal drug isavuconazole works in critically ill adults in intensive care who have a fungal infection (invasive fungal infection). If you are in the ICU with a suspected or confirmed fungal infection, you may be able to join.
Hear when a new ICU Yeast Intra-abdominal Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.